601 results on '"Jazaeri, Amir A."'
Search Results
52. Data from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
53. Supplementary Figure 1 from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
54. Supplementary Figure 2 from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
55. Supplementary Figure Legends from Overcoming Platinum Resistance in Preclinical Models of Ovarian Cancer Using the Neddylation Inhibitor MLN4924
56. Data from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
57. Figure S1 & Figure S2 from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
58. Supplementary Methods from Normal and Cancerous Tissues Release Extrachromosomal Circular DNA (eccDNA) into the Circulation
59. Breast Cancer Classification and Prognosis Based on Gene Expression Profiles from a Population-Based Study
60. Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance
61. Potential immunotherapy targets in recurrent cervical cancer
62. Immunotherapy in locally advanced cervical cancer: Integrating KEYNOTE-A18 into management strategies
63. Figure_S6 from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
64. Supplementary Figure S1 from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
65. Data from Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer
66. Supplementary Tables from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
67. Article Figures 1-4 from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
68. Supplementary Data from Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer
69. Supplementary Figure 3A Gene List from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
70. Data from Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers
71. Supplementary materials from Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer
72. Clinical implications of tumor‐based next‐generation sequencing in high‐grade epithelial ovarian cancer
73. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer
74. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer
75. Immunotherapy in Gynecologic Cancers: Are We There Yet?
76. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine
77. Epigenetic Regulation of GDF2 Suppresses Anoikis in Ovarian and Breast Epithelia
78. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
79. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor–induced colitis
80. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
81. Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma
82. Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression
83. 713 The PRAME opportunity – high peptide copy numbers, homogenous expression and high prevalence to address a broad patient population across different solid cancers with TCR-based therapeutics
84. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival
85. 1094 Favorable preclinical efficacy and safety profile of AVB-001 a novel IL-2 cell-based immunotherapy that eradicates ovarian cancer in mouse tumor models and supports first in human clinical development
86. Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
87. 2022-RA-262-ESGO Predictors of oncologic outcome in recurrent cervical cancer patients receiving phase 1 cancer therapy
88. Adoptive Cell Therapy in Gynecologic Cancers: A Systematic Review and Meta-analysis
89. Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors (099)
90. Colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery? (598)
91. HERO-Trial: Integration of self-hypnosis in an enhanced recovery after surgery program: A prospective randomized trial (115)
92. The devil you know: A population-level analysis of tumor-based next-generation sequencing of high-grade epithelial ovarian cancer (151)
93. Phase Ib study of AVB-S6-500 (axl inhibition) in combination with durvalumab (MEDI4736) in patients with platinum-resistant, recurrent epithelial ovarian cancer (NCT04019288) (320)
94. How to train your robot: Artificial intelligence predicts treatment response in ovarian cancer (069)
95. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials
96. Molecular Profiles of Serum-Derived Extracellular Vesicles in High-Grade Serous Ovarian Cancer
97. CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling
98. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin
99. Erythema nodosum‐like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy—Report of 2 patients
100. Abstract 4189: Evaluation of implantable cytokine factories in combination with checkpoint inhibitors for eradication of malignant pleural mesothelioma (MPM) tumors in mice with safe and predictable dosing in non-human primates
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.